ポイントオブケア脂質検査市場 - 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、適応疾患別、エンドユーザー別、地域別、競合別、2020年～2030年

ポイントオブケア脂質検査の世界市場は、2024年には7億3,561万米ドルとなり、2030年までには10億7,248万米ドルに達すると予測され、CAGRは6.46％を記録します。

同市場は、心血管疾患の罹患率の上昇と脂質レベルの早期検出の重要性の高まりに牽引され、着実に拡大しています。ポイントオブケア（POC）脂質検査は、迅速で正確な診断を提供し、プライマリケアや緊急時の臨床判断をタイムリーにサポートします。健康意識の高まりと予防医療の重視がPOC脂質検査の採用を加速しており、その使いやすさと診断価値の高さから医師と患者の双方から人気を集めています。移動診療所や地域薬局に組み込まれることで、さらに利用しやすくなります。Bluetoothやクラウド機能を備えたポータブル脂質分析計の進歩は、患者のモニタリングや電子カルテとのデータ統合にも変化をもたらしています。複数のバイオマーカーを同時に検査するマルチ分析プラットフォームに対する需要は増加傾向にあり、診断の分散化と価値に基づくヘルスケア提供へのシフトを補完しています。

主要な市場促進要因

心血管疾患と脂質異常症の有病率の上昇

主要な市場課題

正確性と信頼性に関する懸念

主要な市場動向

デジタルヘルス技術の統合

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のポイントオブケア脂質検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（機器、消耗品）
  • 用途別（高脂血症、高トリグリセリド血症、タンジール病、高リポタンパク血症、家族性高コレステロール血症、その他）
  • 適応疾患別（脂質・リポタンパク質疾患、動脈硬化症、肝疾患・腎疾患、糖尿病、その他）
  • エンドユーザー別（病院、診療所、調査・診断研究所、その他）
  • 企業別（2024年）
  • 地域別
• 市場マップ

第6章 北米のポイントオブケア脂質検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のポイントオブケア脂質検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のポイントオブケア脂質検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のポイントオブケア脂質検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのポイントオブケア脂質検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech（Hangzhou）Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases and Dyslipidemia

The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.

Key Market Challenges

Concerns Regarding Accuracy and Reliability

A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.

Key Market Trends

Integration of Digital Health Technologies

The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.

Key Market Players

• Callegari Srl
• Sinocare Inc.
• Abbott Laboratories
• MiCoBio
• Nova Biomedical
• VivaChek Biotech (Hangzhou) Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Menarini Group
• SD Biosensor, Inc.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point of Care Lipid Test Market, By Product:

• Instruments
• Consumables

Point of Care Lipid Test Market, By Application:

• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Hyperlipoproteinemia
• Familial Hypercholesterolemia
• Others

Point of Care Lipid Test Market, By Disease Indication:

• Lipid and Lipoprotein Disorders
• Atherosclerosis
• Liver and Renal Diseases
• Diabetes Mellitus
• Others

Point of Care Lipid Test Market, By End User:

• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others

Point of Care Lipid Test Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.

Available Customizations

Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Point of Care Lipid Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables)
  • 5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
  • 5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
  • 5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Point of Care Lipid Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Disease Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point of Care Lipid Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Disease Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Point of Care Lipid Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Disease Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Point of Care Lipid Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Disease Indication
      • 6.3.3.2.4. By End User

7. Europe Point of Care Lipid Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Disease Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Point of Care Lipid Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Point of Care Lipid Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Point of Care Lipid Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Disease Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point of Care Lipid Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Disease Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Point of Care Lipid Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Disease Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Point of Care Lipid Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point of Care Lipid Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Point of Care Lipid Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Point of Care Lipid Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point of Care Lipid Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease Indication
      • 8.3.5.2.4. By End User

9. South America Point of Care Lipid Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Disease Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point of Care Lipid Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Point of Care Lipid Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Point of Care Lipid Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Point of Care Lipid Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Disease Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point of Care Lipid Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Point of Care Lipid Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Callegari Srl
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Sinocare Inc.
• 15.3. Abbott Laboratories
• 15.4. MiCoBio
• 15.5. Nova Biomedical
• 15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Menarini Group
• 15.9. SD Biosensor, Inc.
• 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer